Form 4: Guardant Health Executive Terilyn J. Monroe Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc., reports the acquisition of stock options and restricted stock units.
Summary
- On February 26, 2024, Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc., reported changes in beneficial ownership to the SEC.
- Monroe was granted stock options for 78,204 shares of common stock at an exercise price of $20.14.
- These options vest over a three-year period, with 33% vesting on January 2, 2025, and the remaining 67% vesting in equal monthly installments over the subsequent two years.
- Monroe also received a grant of 52,136 restricted stock units (RSUs).
- These RSUs vest over a three-year period, with 33% vesting on January 15, 2025, and the remaining 67% vesting annually over the subsequent two years.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, which are generally viewed as a positive for aligning management interests with shareholders.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
This filing does not contain forward-looking statements about the company's future performance; it only reports the grant of stock options and RSUs to an executive.
Industry Context
Stock option and RSU grants are a common practice in the biotech industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like Exact Sciences and Illumina also utilize stock options and RSUs as part of their executive compensation plans.
- The vesting schedules are fairly typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value.
- Employees: The grants can serve as a morale booster, demonstrating the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction (grant of stock options and RSUs) |
| 02/27/2024 | Date of signature on the Form 4 filing |
| 01/02/2025 | First vesting date for 33% of the stock options |
| 01/15/2025 | First vesting date for 33% of the restricted stock units |
| 02/26/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.